|ITCI -- USA Stock|| |
USD 20.28 0.52 2.50%
Mr. Robert E. Davis is Ph.D., is Senior Vice President and Chief Scientific Officer of the Company. He previously served as President and CEO of 3D Pharmaceutical Consultants, providing consulting services to the Company from December 2005 to November 2015. From December 2000 until November 2005, Dr. Davis served as the Executive Vice President, Research and Development at ACADIA Pharmaceuticals. From January 1994 until October 2000, Dr. Davis held various positions at MitoKor, a development stage biotechnology company focused on the design and development of drug therapies for mitochondrial diseases, serving at various times as its President, Chief Executive Officer and Chief Scientific Officer. Earlier, Dr. Davis held various positions at ParkeDavis Pharmaceutical Research, WarnerLambert. Earlier in his career, he participated in the discovery and development of Cognex, the first drug approved for treating Alzheimers disease, Neurontin, the first drug approved for treating neuropathic pain, and Nuplazid, a potential new treatment for psychosis associated with Parkinson disease
Age: 65 President Since 2015 Ph.D
Davis received his B.S., M.S and Ph.D in Psychobiology from the University of Illinois.